Preparing for Brexit

Our Position

Since the UK voted to leave the European Union (EU), LabCorp and its drug development business unit, Covance, (together the Company) has been evaluating the potential impact on the Company and the pharmaceutical industry in Europe and the UK. The Company is confident that it will be prepared to provide its clients with continuing services, regardless of the ultimate results of the negotiations between the UK and the EU. The Company will adapt its Brexit readiness plans as necessary in light of new developments. In line with its mission to improve health and improve lives, the Company supports the industry-wide position that it is crucial that Brexit does not result in any reduction in patient access to safe and effective medicine.

For More Information

For more information, please contact us at

Additional Resources

Interested in medical and in vitro diagnostic devices? Learn how a no-deal Brexit could influence device development.